What is the evidence behind SS-31 / Elamipretide?

Evidence grade B. See our grading methodology for what each grade means.

Is SS-31 / Elamipretide available in 2026?

Approved for one thing, not for longevity. Elamipretide (Forzinity) received FDA accelerated approval on Sep 19, 2025 for Barth syndrome (≥30 kg), a genuine first. Any energy/longevity use is off-label, unproven, and not something we offer as such.

Is SS-31 / Elamipretide FDA-approved?

See the status line above. Compounded and investigational medications are not FDA-approved.

Peptide Knowledge Base · Longevity

SS-31 / Elamipretide: what it is, what the evidence says, and its real status

Short version

A mitochondria-targeting peptide that binds cardiolipin to restore ATP production.

Education onlyEvidence grade B · Good human evidence

That’s the honest answer. Everything below is the detail.

The credibility magnet. A real, fresh FDA approval (elamipretide / Forzinity, Sept 2025), but only for Barth syndrome. Every longevity use is off-label and unproven. We foreground that two-signal nuance: approved is not the same as approved-for-this.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: Approved (Barth) · off-label otherwise.

How does SS-31 / Elamipretide work?

A tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, stabilizing the electron-transport chain to restore ATP output and cut reactive oxygen species.

What it does — and what it does not do

What it does: In Barth syndrome, supports mitochondrial energy production; that is the approved, evidenced use.

What it does not do: It is not approved for aging, energy, or longevity, and the two-signal rule holds: a real approval for one disease is not a green light for off-label use.

How honest is the evidence?

Evidence grade B — Good human evidence.

grade B for Barth syndrome (approval-grade); grade D for longevity (off-label, unproven)

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Longevity and general-energy benefits in healthy adults are not established; the approval is narrow (Barth syndrome).

WADA status: Not prohibited.

How it is taken

What the literature reports for the approved indication: subcutaneous. Educational only, no dose figures.

Who should not take it

Off-label longevity use is not characterized for safety; clinician-gated. Approved use is specialist-managed.

Sources

FDA accelerated approval, elamipretide (Forzinity), Sep 19 2025, Barth syndrome · Stealth BioTherapeutics labeling (re-verify)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.

Cite this page

SS-31 / Elamipretide. Peptós.LIFE Peptide Knowledge Base. Reviewed Jun 18, 2026. https://peptos.life/peptides/ss-31

Free to reuse under CC BY 4.0, with attribution and a link. Machine-readable: JSON · CSV · what is in the export.